Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis

Multiple Sclerosis

Volumn 10, Issue 3, 2004, Pages 266-271

  Zakrzewska Pniewska, Beata ^a   Styczynska, M ^b   Podlecka, A ^a   Samocka, R ^c   Peplonska, B ^b   Barcikowska, M ^b   Kwiecinski, H ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c CSK MSWiA ^*  (Poland)

Author keywords

Apolipoprotein E; Genes; Multiple sclerosis; Myeloperoxidase; Polymorphism

Indexed keywords

APOLIPOPROTEIN E; MYELOPEROXIDASE;

ADULT; AGE; AGED; ALLELE; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMYELINATING DISEASE; DISABILITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ETHNOLOGY; FAMILIAL DISEASE; FEMALE; GENDER; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVOUS TISSUE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OXIDATIVE STRESS; POLAND; REMYELINIZATION; STATISTICAL SIGNIFICANCE; TISSUE INJURY;

ADOLESCENT; ADULT; AGED; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; ATROPHY; BRAIN; FAMILY HEALTH; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEROXIDASE; POLYMORPHISM, GENETIC;

EID: 3042544816     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1015oa     Document Type: Article

References (32)

1. Miller JR. Multiple sclerosis. In Rolland LP ed. Merritt's neurology, tenth edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2000: 773-92.
2. Haines JL, Ter-Minassian M, Bazyk A. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility. The Multiple Sclerosis Genetics Group. Nat Genet 1996; 13: 469-71.
3. Barcellos LF, Thomson G, Carrington M, Schafer J, Begovich AB, Lin P et al. Chromosome 19 single-locus and multilocus haplotype associations with multiple sclerosis. JAMA 1997; 278: 1256-61.
4. Sawcer S, Maranian M, Setakis E, Curwen V, Akesson E, Hensiek A et al. A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain 2002; 125: 1337-47.
5. Carlin C, Murray L, Graham D, Doyle D, Nicoli J. Involvement of apolipoprotein E in multiple sclerosis: absence of remyelination associated with possession of the ApoE E2 allele. J Neuropathol Exp Neurol 2000; 59: 361-76.
6. Kantarci OH, Atkinson EJ, Hebrink DD, McMurray C, Weinshenker BG. Association of am myeloperoxidase promoter polymorphism with multiple sclerosis. J Neuroimmunol 2000; 105: 189-94.
7. McDonald I, Compston A, Edan G, Goodkin D, Hartung HP, Lublin F et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
8. Chapman J, Estupinana J, Asherow A. A simple and efficient method for apolipoprotein E genotype determination. Neurology 1996; 46: 1484-85.
9. Reynolds WF. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 1999; 155: 31-41.
10. Kelly MA, Cavan DA, Penny MA, Mijovic CH, Jenkins D, Morrisey S et al. The influence of HLA-DR and DQ alleles on progression in multiple sclerosis following the clinically isolated syndrome. Hum Immunol 1993; 37: 185-91.
11. Hauser SL, Oksenberg JR, Lincoln R, Garovoy J, Beck RW, Cole SR et al. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group. Neurology 2000; 54: 1859-61.
12. Masterman T, Zhang Z, Hellgren D, Salter H, Anvret M, Lilius L et al. ApoE genotypes and disease severity in multiple sclerosis. Mult Scler 2002; 8: 98-103.
13. Fazekas F, Strasser-Fuchs S, Kolegger H, Berger T, Kristoferitsch W, Schmidt H et al. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 2001; 57: 853-57.
14. Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF et al. ApoE genotype is a major predictor of long-term progression disability in MS. Neurology 2001; 57: 2148-49.
15. Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M et al. ApoE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001; 56: 312-16.
16. Haines JL, Schmidt S, Boylston FR, Rogala A, Rimmler JB, Vance JM et al. Follow-up analysis of the chromosome19q13 region in multiple sclerosis with single-nucleotid polymorphisms. Neurology 2001; 56: A96.
17. Lucotte GL, The French MS Consortium. Confirmation of a gene for multiple sclerosis (MS) to chromosome 19q13.3. Genet Couns 2002; 13: 133-38.
18. Weatherby SJ, Man CL, Davies MB, Fryer AA, Haq N, Strange RC et al. Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis. Mult Scler 2000; 6: 32-36.
19. Schreiber K, Otura AB, Ryder LP, Madsen HO, Jorgensen OS, Svejgaard A et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler 2002; 8: 295-98.
20. Ballerini C, Campani D, Rombola G, Gran B, Nacmias B, Pia Amato et al. Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. Neurosci Lett 2000; 296: 174-76.
21. Reunanen K, Finnila S, Laaksonen M, Sumelahti ML, Wikstrom J, Pastinen et al. Chromosome 19q13 and multiple sclerosis susceptibility in Finland: a linkage and two-stage association study. J Neuroimmunol 2002; 126: 134-42.
22. Haines JL, Bradford Y, Garcia ME, Reed AD, Neumeister E, Pericak-Vance et al. Multiple susceptibility loci for multiple sclerosis. Hum Mol Genet 2002; 11: 2251-56.
23. Chataway J, Mander A, Robertson N, Sawcer S, Deans J, Fraser M et al. A screen of candidates from peaks of linkage: evidence for the involvement of myeloperoxidase in multiple sclerosis. J Neuroimmunol 1999; 98: 208-13.
24. Saarrela J, Schoenberg Fejzo M, Chen D, Finnila S, Parkkonen M et al. Fine mapping of a multiple sclerosis locus to 2.5 Mb on chromosome 17q22-q24. Hum Mol Genet 2002; 11: 2257-67.
25. Brennan M, Gaur A, Pahuja A, Lusis AJ, Reynolds WF. Mice lacking myeloperoxidase are more susceptible to experimental autoimmune encephalomyelitis. J Neuroimmunol 2001; 112: 97-105.
26. Hoy A, Leininger-Muller B, Kutter D, Siest D, Visvikis S. Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 2002; 40: 2-8.
27. Nelisssen I, Fiten P, Vandenbroeck K, Hillert J, Olsson T, Marrosu MG et al. PECAM1, MPO and PRKARIA at chromosome 17q21-q24 and susceptibility for multiple sclerosis in Sweden and Sardinia. J Neuroimmunol 2000; 108: 153-59.
28. Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T et al. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 1997; 78: 97-107.
29. Pullar JM, Vissers MC, Winterbourn CC. Living with a killer: the effects of hypochlorous acid on mammalian cells. IUBMB Life 2000; 50: 259-66.
30. Kumagai S, Jikimoto T, Saegusa J. Pathological roles of oxidative stress in autoimmune diseases. Rinsho Byori 2003; 51: 126-32.
31. Mann CL, Davies MB, Boggild MD, Alldersea J, Fryer AA, Jones PW et al. Glutathione S-transferase polymorphisms in MS: their relationship to disability. Neurology 2000; 54: 552-57.
32. Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD et al. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci 2003; 23: 3597-606.